Releases - MOBERG DERMA AB

The pharmaceutical company Moberg Derma completed the second tranche of its share issue according to plan. During 2009, a total of SEK 40 million has been secured. The second tranche of SEK 10 million was directed primarily to existing shareholders. More than SEK 110 million has been raised since the company was established in March 2006.

“We are very pleased with the strong support from our investors. Through the...

Moberg Derma AB reports today positive results from a phase II clinical study for K201 against atopic eczema. The study which included 30 patients with mild to moderate eczema showed that treatment with K201 resulted in statistically significant improvement of clinical skin condition, skin barrier and skin hydration. The study results also indicated that K201 can prevent growth of commonly occurring bacteria in...

The pharmaceutical company Moberg Derma has received a grant of SEK 4,2 million from Vinnova (The Swedish Governmental Agency for Innovation Systems). The grant will be used to develop an innovative patent-protected pharmaceutical product that will further strengthen the company’s position in the area of topical antifungals.
“We are very pleased that we have been awarded this grant which enables a faster...

The pharmaceutical company Moberg Derma recently secured SEK 35 million in a new share issue. Both existing and new shareholders subscribed for shares in the issue. More than SEK 100 million has now been raised for its operations since the company was established in March 2006.
“We are very pleased with the interest shown by investors what has been a difficult market climate in recently. The new share issue has...

Moberg Derma AB today announces a license and co-promotion agreement with a leading Nordic OTC company for K101 - Moberg Derma’s novel treatment for nail fungus (onychomycosis). In the agreement, Moberg Derma will be responsible for supply of the product and promotion to prescribers, while its Nordic partner will be responsible for promotion to consumers. Financial terms are not disclosed but include up-front and...

Moberg Derma AB and MedPharm Ltd today announce a license and distribution agreement for the development, marketing and sales of new dermatology products that will combine Moberg Derma’s Kaprolac® platform with MedPharm’s MedSpray™ technology. According to the agreement, MedPharm will be eligible for royalty payments.
Moberg Derma obtains the exclusive rights to worldwide manufacturing, distribution and sales...

Moberg Derma AB today announces the acquisition of two pharmaceutical projects in preclinical phase from Zelmic AB (Lund, Sweden). Zelmic will assist Moberg Derma in the future development of the projects. The two companies also agreed on a long term collaboration on future development projects. Financial terms were not disclosed.
“We have worked with the Zelmic team for some time and are impressed by their...